Rivoglitazone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Rivoglitazone
Rivoglitazone.svg
Systematic (IUPAC) name
(RS)-5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl) methoxy]benzyl}-1,3-thiazolidine-2,4-dione
Identifiers
CAS Number 185428-18-6
ATC code none
PubChem CID 3055168
ChemSpider 2316729
UNII 3A3N0634Q6 YesY
ChEMBL CHEMBL2104753
Chemical data
Formula C20H19N3O4S
Molar mass 397.448 g/mol
  (verify)

Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.[1][2]

It is being developed by Daiichi Sankyo.

References[edit]

  1. ^ Schimke K; Davis ™ (2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Curr Opin Investig Drugs. 8 (4): 338–44. PMID 17458185. 
  2. ^ Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, Ko GT, Wong CK, Leung GT, Lee KF, Yeung CY, Chan JC (2011). "A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes". Diabetes Obes Metab. 13 (9): 806–13. doi:10.1111/j.1463-1326.2011.01411.x. PMID 21492364.